Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel, HLA Typing and Epitope Mapping Relative to HIV Vaccine Design.
Date: December 11, 2002.
Time: 12:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate contract proposals.
Place: NIAID, DEA, SRP, 6700B Rockledge Drive, Rm. 2148A, Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Katherine L. White, PhD, Scientific Review Administrator, AIDS Preclinical Research Review Branch, Scientific Review Program, National Institutes of Allergy and Infectious Diseases, Room 3119, Bethesda, MD 20892, (301) 435-1615, firstname.lastname@example.orgStart Signature
(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)
Dated: November 21, 2002.
LaVerne Y. Stringfield,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 02-30240 Filed 11-27-02; 8:45 am]
BILLING CODE 4140-01-M